The MS Center offers the most current treatment protocols available for multiple sclerosis, including approved and novel investigational therapies. The Center includes physician-scientists in immunobiology, pathology, diagnostic radiology, computational biology and genetics to engage in basic research and clinical trials to advance both the understanding of the disorder and continually improve treatment options.
The Center has participated in pivotal trials in many of the currently approved drugs for MS, including glatiramer acetate (Copaxone®), interferon, including Avonex®, mitoxantrone (Novantrone®), and natalizumab (Tysabri®), as well as oral disease-modifying therapy, fingolimod (Gilenya®) and BG-12 (Tecfidera®).
View the Yale School of Medicine Department of Neurology video Immune Cells in the MS Nervous System.
Contact Us
